Minde Zeng's research while affiliated with Shanghai Jiao Tong University and other places

Publications (18)

Article
Full-text available
Objective In China, polyene phosphatidylcholine (PPC) is widely used to treat alanine aminotransferase (ALT) elevation associated with various liver diseases. Here, we assessed the efficacy and safety of PPC in treating drug-induced liver injury (DILI). Methods Data from a multicenter retrospective cohort study (DILI-R) were analyzed to compare PPC...
Article
Full-text available
Background To determine the safety and efficacy of different doses of tolvaptan for treating Chinese cirrhotic patients with or without hyponatraemia who still had ascites after routine therapy with diuretics. Methods In the present placebo-controlled, randomized, double-blinded, multicentre clinical trial, patients with cirrhotic ascites who fail...
Article
Background: Drug-induced liver injury (DILI) is the most common reason for a drug to be withdrawn from the market. Aside from stopping the offending drug, no regimens are available for treating idiosyncratic DILI in clinical practice. Methods: We carried out a randomized, double-blind, multi-doses, active drug controlled, multi-center phase II t...
Article
Aim: To evaluate tolvaptan as a novel therapeutic option for Chinese patients with liver cirrhosis-associated ascites in a phase 2 clinical trial. Methods: This randomized, double-blind, placebo-controlled, multicenter trial was conducted in patients with insufficient responses to combination therapies of an oral loop diuretic and an aldosterone...
Article
Full-text available
Aim Tauroursodeoxycholic acid (TUDCA) is a taurine conjugated form of ursodeoxycholic acid (UDCA) with higher hydrophility. To further evaluate the efficacy and safety of TUDCA for primary biliary cholangitis (PBC), we performed this study on Chinese patients. Methods 199 PBC patients were randomly assigned to either 250 mg TUDCA plus UDCA placebo...
Article
Full-text available
Noninvasive models have been developed for fibrosis assessment in patients with chronic hepatitis B. However, the sensitivity, specificity and diagnostic accuracy in evaluating liver fibrosis of these methods have not been validated and compared in the same group of patients. The aim of this study was to verify the diagnostic performance and reprod...
Data
AUROC of ten noninvasive models in the diagnosis of significant fibrosis (F2-4), advanced fibrosis (F3-4), and cirrhosis (F4). (TIF)
Data
AUROC of respective models was compared with each other and the P values was listed. (DOCX)
Article
Full-text available
Non-alcoholic fatty liver (NAFL) has the potential to progress to non-alcoholic steatohepatitis (NASH) or to promote type 2 diabetes mellitus (T2DM). However, NASH and T2DM do not always develop coordinately. Additionally, there are no definite noninvasive methods for NASH diagnosis currently. We established rat models of NAFL, NASH, and NAFL + T2D...
Article
Nonalcoholic fatty liver disease (NAFLD) is a mitochondrial disease associated with the metabolic syndrome, but few data are available on the mitochondrial dysfunction of NAFLD after the development of type 2 diabetes mellitus (T2DM). We aimed to identify the changes of mitochondrial function in rat livers when T2DM develops after NAFLD. Rat models...
Article
Full-text available
Background and aimLiver stiffness measurement (LSM) using transient elastography (FibroScan®) is a useful tool to assess fibrosis in various chronic liver diseases. However, studies were mainly performed in Western countries and largely focused on chronic hepatitis C (CHC). We therefore carried out a multi-center study to validate the accuracy of L...
Article
The safety and pharmacokinetics of magnesium isoglycyrrhizinate were assessed in healthy Chinese volunteers. In the single-dose format of this pharmacokinetic study, 100-, 200-, and 300-mg doses of magnesium isoglycyrrhizinate were given by intravenous infusion. The results indicated that the plasma levels were directly proportional to the administ...
Article
Four hundred and eighty Chinese subjects with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) were enrolled in a multicenter, double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) 10 mg once daily. There was a significant difference in reduction of serum hepatitis B virus (HBV) DNA after 12 weeks between su...
Article
To evaluate the long-term efficacy and safety of lamivudine therapy for the treatment of chronic hepatitis B and the clinical influence of emergence of tyrosine methionine aspartic acid (YMDD) motif mutation of hepatitis B virus (HBV). This multicenter, double-blind, randomized, placebo controlled trial began in 1996. A total of 429 patients with H...
Article
To investigate the prophylactic and therapeutic effect of oxymatrine on experimental liver fibrosis and to reveal its mechanism. By establishing D-galactosamine-induced rat liver fibrosis model, we observed the effect of oxymatrine on serum and tissue biochemical indexes, content of liver hydroxyline, expression of TGF?1 mRNA and changes of tissue...

Citations

... The Clinical Efficacy of Tolvaptan in Cirrhosis Tolvaptan (7.5-30 mg/day for 7 days) has been shown to have add-on effects to conventional diuretics on ascites in Japanese multicenter randomized control trials (RCTs) ( Table 1) [49,50]. Significant body weight loss was also reported in a Chinese multicenter RCT [51]. The effectiveness of tolvaptan has been defined differently in different studies. ...
... pg/mL, 11.36 vs. 12.08 pg/mL, respectively) (Lv et al. 2017). Recently, Wang et al. (2019) evaluated the safety and efficacy of magnesium isoglycyrrhizinate at 100 mg/ day (group A), and 200 mg/day (group B) in patients with acute drug-induced liver damage. After 4 weeks, magnesium isoglycyrrhizinate ALT was normalized significantly in group A and group B with 84.75%, p = 0.0029 and 85.71%, p = 0.0037, respectively. ...
... Tolvaptan was approved in China in September 2011 to treat hypervolemic and euvolemic hyponatraemia caused by liver cirrhosis, heart failure or syndrome of inappropriate antidiuretic hormone in a dose range of 15-60 mg/ day [10]. From March 2009 to February 2010, China carried out a phase II ascites trial that showed that tolvaptan was effective and safe for treating Chinese ascites patients, with no differences between a 15 mg/day or 30 mg/day therapy regimen [11]. At the time of the initiation of this study (October 2010), tolvaptan had not been approved in Japan for the treatment of ascites. ...
... Currently, there is one clinical trial evaluating its use in PSC patients (NCT01755507). A recent study has shown that TUDCA was able to normalize serum ALP values in PBC patients [43]. Another FXR agonist with therapeutic potential in the treatment of cholestatic diseases is the semi-synthetic BA, obeticholic acid (OCA). ...
... Liver biopsy is the gold standard for assessing fibrosis but is not widely accepted owing to its invasive nature, rare but potentially lifethreatening complications, and prone to sampling errors. [11,12] Therefore, the development of non-invasive liver fibrosis prediction models could be favorable for this population. ...
... Furthermore, S100A9 promotes inflammation and lipolysis in the liver during NAFLD progression (Wu et al., 2020). Another study demonstrated that S100A9 can differentiate hepatic and metabolic progression in NAFLD as a biomarker in NAFLD progression (Liu et al., 2015). Additionally, studies have shown that S100A12 interacts with S100A9 (Hatakeyama et al., 2004) and also has proinflammatory activity (Miranda et al., 2001). ...
... Garnol et al. 43 have reported a decreased activity of complex I in hepatocytes isolated from rats fed a high fat diet compared with the controls fed a standard diet. In addition, Liu et al. 44 have reported that a 12 week high fat diet intake impaired the activities of the mitochondrial respiratory chain and β-oxidation in NAFLD in rats. ...
... The treatment history may affect the diagnostic accuracy of 2D-SWE for staging fibrosis. ALT could affect the LS values measured by TE, which are mainly reported in patients with chronic hepatitis B [32][33][34]. However, the ALT did not associate with LS in this study. ...
... Antifibrotic activity of oxymatrine in d-galactosamine-induced rat liver fibrosis has been predicted to be partly through inhibition of lipid peroxidation. Immune-stimulative activity that changes the immune response of HBV-transgenic mice from a Th2 (IL-4 and IL-10) to a Th1 (IFN-γ and IL-2) response has been also reported (Dong et al., 2002;Yang et al., 2002). Because these animal studies and cell-based experiments showed promising effects against HCV infection, several clinical studies have been conducted Mao et al., 2004). ...
... However, because of the retrospective nature of the analyses, subjects were not treated solely with 3TC and response achieved may also reflect the late effects of interferon. Hepatitis e antigen/antibody seroconversion rate is reported to vary between 17.4% and 33% in the second and third year of monotherapy with 3TC[13,18]. We observed 5.6% seroconversion during the second and none in the third year. ...